Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024)
Invivyd's (IVVD) quarterly Total Non-Current Liabilities came in at $62.0 million in Q4 2024, up 21.49% on a YoY basis from $51.0 million in Q1 2024, and down 21.31% quarter-over-quarter from $78.8 million in Q3 2024.
Analysis
Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Invivyd (IVVD) has reported Total Non-Current Liabilities for 5 consecutive years, with $62.0 million the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Total Non-Current Liabilities rose 21.49% year-over-year to $62.0 million; the trailing twelve-month figure through Dec 2024 stood at $62.0 million (up 21.49% YoY), and the FY2024 full-year result was $62.0 million, up 21.49% from the prior year.
- Total Non-Current Liabilities fell to $62.0 million in Q4 2024 per IVVD's latest filing, from $78.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $96.9 million in Q1 2022 and bottomed at $13.1 million in Q4 2020.
- Historically, Total Non-Current Liabilities has averaged $50.8 million across 5 years, with a median of $49.2 million in 2022.
- The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities surged 374.4% in 2021, then slumped 56.18% in 2022.
- Over 5 years, Total Non-Current Liabilities stood at $13.1 million in 2020, then soared by 374.4% to $62.1 million in 2021, then tumbled by 56.18% to $27.2 million in 2022, then jumped by 87.57% to $51.0 million in 2023, then rose by 21.49% to $62.0 million in 2024.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $62.0 million, $78.8 million, and $36.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 61.98 Mn |
| Sep 30, 2024 | 78.76 Mn |
| Jun 30, 2024 | 36.70 Mn |
| Mar 31, 2024 | 36.97 Mn |
| Dec 31, 2023 | 51.01 Mn |
| Sep 30, 2023 | 27.72 Mn |
| Dec 31, 2022 | 27.20 Mn |
| Sep 30, 2022 | 47.30 Mn |
| Jun 30, 2022 | 69.77 Mn |
| Mar 31, 2022 | 96.88 Mn |
| Dec 31, 2021 | 62.07 Mn |
| Dec 31, 2020 | 13.08 Mn |